Cyclopeptide Utilizing Patents (Class 514/2.9)
-
Publication number: 20130296228Abstract: Novel compositions and methods of reducing microbial resistance to antimicrobial agents and treating infections are disclosed. In particular, compositions and methods of inhibiting efflux pump activity, treating infection and methods of enhancing antimicrobial activity of antimicrobial agents are provided.Type: ApplicationFiled: April 22, 2013Publication date: November 7, 2013Inventors: Mahesh Vithalbhai PATEL, Sachin Subhash Bhagwat, Mohammad Alam Jafri
-
Patent number: 8575094Abstract: A method for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject is described, wherein the method comprises administration to the subject of a type-B lantibiotic, wherein the type-B lantibiotic may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.Type: GrantFiled: January 21, 2009Date of Patent: November 5, 2013Assignee: Novacta Biosystems LimitedInventors: Sjoerd Nicolaas Wadman, Michael John Dawson, Jesus Cortes Bargallo
-
Publication number: 20130288955Abstract: A novel pharmaceutical composition comprising a compound of formula (I) is disclosed. The novel compound can include a pharmaceutically acceptable carrier. The invention further comprises methods for making compounds of formula (I) using Dbv29, and to the use of compound of formula (I) to treat bacterial infections.Type: ApplicationFiled: July 10, 2013Publication date: October 31, 2013Inventors: Tsung-Lin Li, Yu-Chen Liu, Yi-Shan Li, Syue-Yi Lyu
-
Publication number: 20130287866Abstract: Use of nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation, such as peripheral vascular disease. The nitric oxide amino acid esters may be co-administered with an antimicrobial in topical or transdermal compositions for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation.Type: ApplicationFiled: October 26, 2011Publication date: October 31, 2013Applicant: ORAL DELIVERY TECHNOLOGY LTD.Inventor: Michael Farber
-
Publication number: 20130281360Abstract: Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectrum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided.Type: ApplicationFiled: August 31, 2011Publication date: October 24, 2013Applicant: The Scipps Research InstituteInventors: Floyd E. Romesberg, Peter A. Smith, Tucker C. Roberts
-
THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE
Publication number: 20130274174Abstract: A therapeutic combination comprises an antibacterially effective amount of daptomycin, and an amount of protein synthesis inhibitor antibiotic effective to prevent the development of daptomycin non-susceptibility in bacteria. Related combination therapies and methods are also included.Type: ApplicationFiled: June 6, 2013Publication date: October 17, 2013Inventors: Kenneth F. Bartizal, Jeffrey B. Locke, Karen Joy Shaw, Philippe G. Prokocimer -
Publication number: 20130252883Abstract: The present application describes a method of treating a bacterial infection comprising administering to a subject in need thereof a pharmaceutically acceptable amount of a defined macrocycle compound.Type: ApplicationFiled: May 23, 2013Publication date: September 26, 2013Inventors: Roger Aki Fujimoto, Philipp Krastel, Matthew J. LaMarche
-
Publication number: 20130244929Abstract: The present invention provides novel lipoglycopeptide compounds which are Type 1 signal peptidase inhibitors (SpsB). Compounds of the present invention are useful for the treatment of various bacterial related infectious diseases, particularly when used as a potentiator of a ?-lactam antibiotic such as imipenem and ertapenem. Accordingly, the present invention provides a method for the treatment of bacterial related infections using the compounds described herein, either alone or in combination with a ?-lactam antibiotic.Type: ApplicationFiled: March 4, 2011Publication date: September 19, 2013Inventors: Michel Gallant, Karine Villeneuve, Patrick Beaulieu, Joel Robichaud, Helene Juteau, Yves Gareau, Sherman T. Waddell, Nancy Kevin, Xin Gu, Joann Huber, Michael J. Salvatore, JR., Kenneth Wilson, Scott K. Smith, Deborah Zink
-
Publication number: 20130231276Abstract: Bacterial multidrug resistance is attenuated in a subject by administering an aminoacyl-tRNA synthetase inhibitor and an antibacterial agent to the subject, wherein the aminoacyl-tRNA synthetase inhibitor is distinct from the antibacterial agent.Type: ApplicationFiled: April 12, 2013Publication date: September 5, 2013Applicant: Brown UniversityInventors: Jason K. Sello, James J. Vecchione
-
Patent number: 8518873Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.Type: GrantFiled: September 11, 2008Date of Patent: August 27, 2013Assignee: The Medicines CompanyInventors: Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr
-
Publication number: 20130217620Abstract: The present invention relates to ionic silicone hydrogel contact lenses which comprise at least one pharmaceutical or nutriceutical component and are formed from reaction mixtures comprising a mixture of slow-reacting hydrophilic monomers, including at least one slow-reacting ionic monomer, at least one silicone-containing component and at least one hydroxyl-containing component, wherein the ratio of the slow-reacting hydrophilic component half lives to the silicone-containing component half life is at least 2.Type: ApplicationFiled: March 14, 2013Publication date: August 22, 2013Applicant: Johnson & Johnson Vision Care, Inc.Inventor: Johnson & Johnson Vision Care, Inc.
-
Patent number: 8513184Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.Type: GrantFiled: December 8, 2011Date of Patent: August 20, 2013Assignees: Gilead Sciences, Inc., Selcia LimitedInventors: Todd Appleby, Hans G. Fliri, Andrew J. Keats, Linos Lazarides, Richard L. Mackman, Simon N. Pettit, Karine G. Poullennec, Jonathan Sanvoisin, Victoria A. Steadman, Gregory M. Watt
-
Publication number: 20130209537Abstract: The present invention relates to the preparation and use of antibiotic-containing nanoparticles for coating an implant including cranial implants and bone graft sites to provide for the extended release of antibiotics to treat infection.Type: ApplicationFiled: July 1, 2011Publication date: August 15, 2013Inventor: Patty Fu-Giles
-
Publication number: 20130203654Abstract: Provided are: a novel compound having a structure different from that of existing drugs; a novel microorganism capable of producing the novel compound; and further; a novel compound effective to a multiple-drug-resistant bacterium. To provide a novel compound having a high therapeutic effect which can be expected to have a low hurdle for practical realization by selecting an intended compound from many candidate compounds based not only on an antibacterial activity but also on evaluation including a therapeutic effect, a cyclic peptide compound shown by the following formula (1) or a pharmaceutically allowable salt thereof and a microorganism with Accession No. NITE BP-870 or a microorganism mutated naturally or artificially therefrom are provided. (In the formula (1), R1 represents an acyl group having 7, 8, or 9 carbon atoms and optionally containing a substituent group; R2 represents a methyl group or a hydrogen atom; and R3 represents an ethyl group or a methyl group.Type: ApplicationFiled: May 25, 2011Publication date: August 8, 2013Applicants: THE UNIVERSITY OF TOKYO, GENOME PHARMACEUTICALS INSTITUTE CO., LTD.Inventors: Kazuhisa Sekimizu, Hiroshi Hamamoto, Kazuhisa Murakami
-
Patent number: 8481483Abstract: The present invention provides cyclosporin analogues of formula I, and compositions comprising these compounds, as well as processes for their preparation, intermediates in their synthesis, and methods of use thereof for prevention of organ transplantation rejection, the treatment of immune disorders and inflammation, and treatment of viral (particularly hepatitis C viral) infection.Type: GrantFiled: February 19, 2010Date of Patent: July 9, 2013Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, Guoqiang Wang, Xuri Gao, Jiang Long
-
Publication number: 20130171252Abstract: Described is a pharmaceutical formulation of a capsule for oral delivery of a type B lantibiotic to the stomach comprising a hard gelatine, HPMC or starch capsule, and a type B lantibiotic of formula (I): wherein X is —NH(CH2)qNH2 and q is an integer 2 to 12.Type: ApplicationFiled: July 12, 2011Publication date: July 4, 2013Applicant: NOVACTA BIOSYSTEMS LIMITEDInventors: Antony Nicholas Appleyard, Sjoerd Nicolaas Wadman
-
Publication number: 20130150283Abstract: This invention discloses isolated short peptides comprising the amino acid sequence Cys-Glu-Phe-His (CEFH; SEQ ID NOS: 1 and 15) and analogs thereof as well as compositions comprising CEFH peptides and analogs thereof. The CEFH peptides disclosed herein are effective in mediating the denitration of 3-nitrotyrosines (3-NT) in cellular proteins thereby preventing tissue damage associated with excess nitric oxide (NO) and its reactive species. The CEFH peptides disclosed herein are useful in the treatment of ischemia/reperfusion (I/R) injury and other disorders.Type: ApplicationFiled: January 31, 2013Publication date: June 13, 2013Applicant: NEW YORK UNIVERSITYInventor: New York University
-
Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
Patent number: 8461188Abstract: A therapeutic combination comprises an antibacterially effective amount of daptomycin, and an amount of protein synthesis inhibitor antibiotic effective to prevent the development of daptomycin non-susceptibility in bacteria. Related combination therapies and methods are also included.Type: GrantFiled: October 19, 2012Date of Patent: June 11, 2013Assignee: Trius Therapeutics, Inc.Inventors: Kenneth F Bartizal, Jeffrey B Locke, Karen Joy Shaw, Philippe G Prokocimer -
Publication number: 20130137630Abstract: Described is a A liquid colloidal pharmaceutical formulation of a type B lantibiotic for infusion or direct injection comprising a type B lantibiotic or a salt thereof, an isotonic aqueous solution comprising a sugar alcohol such as glycerol and/or a saccharide and optionally a buffer, wherein said final formulation for infusion or direct injection is clear of visual particulates.Type: ApplicationFiled: August 9, 2011Publication date: May 30, 2013Applicant: NOVACTA BIOSYSTEMS LIMITEDInventors: Antony Nicholas Appleyard, Sjoerd Nicolaas Wadman
-
Publication number: 20130129695Abstract: The invention provides methods for treating or inhibiting infection by Clostridium difficile in a subject in need of such treatment, comprising administering an effective amount of a compound binding to a CD3299 riboswitch, as well as assays for identifying compounds useful in such treatment, and the use of particular compounds in such treatment.Type: ApplicationFiled: February 4, 2011Publication date: May 23, 2013Inventor: Kenneth Blount
-
Publication number: 20130109617Abstract: Methods and compositions for the treatment of Bacillus anthracis infections are described.Type: ApplicationFiled: October 10, 2007Publication date: May 2, 2013Inventors: Michael N. Alekshun, S. Ken Tanaka
-
Patent number: 8431529Abstract: The present disclosure provides compound having the general structure A or pharmaceutically acceptable salts thereof: Het-L-P??(A) wherein Het is an aromatic moiety comprising a heterocyclic structure mimicking ATP, P is a docking site derived peptide or a docking site peptide mimetic, and L is a linking moiety, wherein L links the ATP mimetic to the docking site peptide moiety. The compounds having the general structure A can serve as inhibitors of kinases, such as the kinases JNK, Erk and p38.Type: GrantFiled: December 16, 2010Date of Patent: April 30, 2013Assignee: Sanford-Burnham Medical Research InstituteInventor: Maurizio Pellecchia
-
THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE
Publication number: 20130102523Abstract: A therapeutic combination comprises an antibacterially effective amount of daptomycin, and an amount of protein synthesis inhibitor antibiotic effective to prevent the development of daptomycin non-susceptibility in bacteria. Related combination therapies and methods are also included.Type: ApplicationFiled: October 19, 2012Publication date: April 25, 2013Applicant: TRIUS THERAPEUTICS, INC.Inventor: Trius Therapeutics, Inc. -
Publication number: 20130096052Abstract: The present invention relates to the determination of the level of marker peptides in a sample derived from a bodily fluid of a subject presenting with non-specific complaints.Type: ApplicationFiled: March 8, 2011Publication date: April 18, 2013Applicant: B.R.A.H.M.S GMBHInventors: Joachim Struck, Christian Nickel, Roland Bingisser, Sven Giersdorf, Oliver Hartmann
-
Patent number: 8415294Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.Type: GrantFiled: June 5, 2008Date of Patent: April 9, 2013Assignee: Arizona Board of RegentsInventors: George R. Pettit, Rui Tan, Robin K. Pettit
-
Patent number: 8410044Abstract: The invention concerns new Bacitracin compounds containing methylene-isoleucine.Type: GrantFiled: September 30, 2010Date of Patent: April 2, 2013Assignee: Xellia Pharmaceuticals ApsInventors: Martin Mansson, Christine Senstad
-
Publication number: 20130072423Abstract: The present invention relates to the use of peptide compounds for the prevention and/or treatment of a bacterial infection.Type: ApplicationFiled: November 9, 2012Publication date: March 21, 2013Applicant: KARLSRUHER INSTITUT FUR TECHNOLOGIEInventor: Karlsruher Institut fur Technologie
-
Patent number: 8394763Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of a cyclosporin compound.Type: GrantFiled: September 26, 2008Date of Patent: March 12, 2013Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veterans AffairsInventors: Michael Forte, Dennis Bourdette, Gail Marracci
-
Publication number: 20130059774Abstract: Novel compositions and methods of reducing microbial resistance to antimicrobial agents and treating infections are disclosed. In particular, compositions and methods of inhibiting efflux pump activity, treating infection and methods of enhancing antimicrobial activity of antimicrobial agents are provided.Type: ApplicationFiled: April 1, 2010Publication date: March 7, 2013Inventors: Mahesh Vithalbhai Patel, Sachin Subhash Bhagwat, Mohammad Alam Jafri
-
Publication number: 20130059775Abstract: The present invention relates to complexes of transcription factor decoys, their delivery to bacteria and their formulation. In particular, the present invention resides in an antibacterial complex comprising a nucleic acid sequence and one or more delivery moieties selected from quaternary amine compounds; bis-aminoalkanes and unsaturated derivatives thereof, wherein the amino component of the aminoalkane is an amino group forming part of a heterocyclic ring; and an antibacterial peptide.Type: ApplicationFiled: February 11, 2011Publication date: March 7, 2013Inventor: Michael McArthur
-
Publication number: 20130053305Abstract: Compounds of formula (I), where: R0 is (C8-C11)-branched alkyl, CH3—(CH2)m—, CH3—O—(CH2CH2O)2CH2—, or phenyl-(CH2)x—; m=6-10; x=1-3; R1, R3, R4, R7, and R8 are independently selected from the formula GF-(CH2)n—; with n=1-4; and GF=—NH2 or —NH—C(?NH)—NH2; R2 is —CH(CH3)(OH), —CH(CH3)2, —CH2NH2 o —CH2OH; R5 and R6 are independently selected among H, —(C1-C4)— linear or branched alkyl, —(CH2)—R10, —CH2—CH2—S—CH3 and —CH—(CH3)—OH; R9 is CONH2, —CH(CH3)(OH) or CONHR11; R10 is phenyl, 3-indolyl, 4-imidazolyl, 4-hydroyiphenyl, ? o ?-naphtyl or 2-, 3- or 4-pyridyl; R11 is a specific peptide sequence; u is CH2 or S; v is NH o S; w is CH2 or CO; with the condition that when R9 is CONH2, then (a) R5 or R6 is —CH(CH3)(OH), or (b) R5 and R6 are H; or (c) the configuration of the C bound to R9 is S or (d) the configuration of the C bound to R5 is R; and with the condition that when R9 is —CH(CH3)OH, then R8 is GF(CH2)n where n is 3 and GF is —NH—C(?NH)—NH2, and R7 is GF(CH2)n where n is 2 and GF is NH2, have been found toType: ApplicationFiled: March 9, 2011Publication date: February 28, 2013Applicant: UNIVERSIDAD DE BARCELONAInventors: Francesc Rabanal Anglada, Yolanda Cajal Visa, Maria Garcia Subirats, Montserrat Rodrígues Núñez
-
Patent number: 8377455Abstract: New Bacillus licheniformis strain named V9T14 that produces a new biosurfactant composition that is effective against colonization and/or bio film formation from bacteria. The new biosurfactant composition can be used in combination with biocides for preventing formation and/or for eradicating bacteria grown planktonically and/or as a biofilm, preferably on biotic and/or abiotic surfaces.Type: GrantFiled: November 25, 2009Date of Patent: February 19, 2013Assignees: PAN-ECO S.A., University Technologies International LPInventors: Howard Ceri, Raymond J Turner, Maria Giovanna Martinotti, Fabrizio Rivardo, Gianna Allegrone
-
Publication number: 20130005647Abstract: A Nisin derivative or variant, comprising an amino acid substitution at amino acid position 29 in the amino acid sequence. The Nisin derivative exhibits enhanced antimicrobial activity when compared to wild type Nisin. The Nisin derivative has an application as a natural food additive and as a therapeutic agent.Type: ApplicationFiled: December 22, 2010Publication date: January 3, 2013Applicants: University College Cork, National University of Ireland, Teagasc, The Agriculture and Food Development AuthorityInventors: Colin Hill, Paul Cotter, Paul R. Ross, Desmond Field
-
Patent number: 8343912Abstract: Provided herein is an antibacterial compound of the following formula: or a pharmaceutically acceptable salt thereof. The antibacterial compound has antibacterial properties against a diverse range of gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin B. Also provided are antibacterial pharmaceutical compositions containing the antibacterial compound, as well as methods for preparing the antibacterial compound.Type: GrantFiled: December 22, 2009Date of Patent: January 1, 2013Assignee: Biosource Pharm, Inc.Inventor: Richard A. Leese
-
Publication number: 20120328671Abstract: The invention relates to products comprising an antibiotic agent and a second agent being a dispersant or an anti-adhesive agent, in particular a mucolytic dispersant or a mucolytic anti-adhesive agent, which are useful in relation to the prevention and treatment of bacterial infections.Type: ApplicationFiled: June 1, 2012Publication date: December 27, 2012Applicant: NOVABIOTICS LIMITEDInventors: Deborah O'Neil, Cedric Charrier
-
Publication number: 20120321596Abstract: A kit for bonding to biological hard tissues, containing a phosphorylated polysaccharide, a polyvalent metal salt other than phosphates, and a solvent. The adhesive composition for biological hard tissues provided by the kit for bonding to biological hard tissues is suitably used in for medical uses, such as cement for bones or dental cement.Type: ApplicationFiled: February 22, 2011Publication date: December 20, 2012Applicants: Junsei Educational Institution, National University Corporation Okayama UniversityInventors: Yasuhiro Yoshida, Masato Tanaka, Kazuomi Suzuki, Toshifumi Ozaki, Tomohiro Takahata, Masao Irie, Mariko Nakamura, Mitsunobu Kawashima, Yamato Nojiri, Koichi Okada, Masahiro Nagao
-
Publication number: 20120316106Abstract: Improved antibiotic analogs, and synergistic combinations of antibiotics designed based on structural crystallographic analysis, are provided as well as pharmaceutical compositions that include these improved analogs and synergistic combinations, along with methods for their production and use. The synergistic combinations target neighboring sites in the ribosome demonstrating the importance of the corresponding ribosomal sites for development of clinically-relevant synergistic antibiotics.Type: ApplicationFiled: December 29, 2010Publication date: December 13, 2012Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Ada Yonath, Chen Davidovich, Ella Zimmerman, Anat Bashan, Tamar Auerbach, Matthew Belousoff, Liqun Xiong, Dorota Klepacki, Alexander S. Mankin
-
Publication number: 20120316103Abstract: The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.Type: ApplicationFiled: August 22, 2012Publication date: December 13, 2012Applicant: NOVABIOTICS LIMITEDInventor: Deborah O'NEIL
-
Publication number: 20120316105Abstract: The present invention provides a new class of polymyxin derivates useful for treating bacterial infections, especially Gram-negative infections, that have reduced renal cytotoxicity.Type: ApplicationFiled: June 7, 2012Publication date: December 13, 2012Inventors: Thomas Victor Magee, Jinshan Michael Chen, Carlos Alberto Martinez, Zhengong B. Li
-
Patent number: 8329645Abstract: The present invention relates to a polymyxin derivative wherein R1, R2 and R3 are optional and R1, R2, R3, R5, R8 and R9 are cationic or neutral amino acid residues selected so that the total number of positive charges at physiological pH is at least two but no more than three; and to a combination product comprising at least two such derivatives.Type: GrantFiled: February 5, 2009Date of Patent: December 11, 2012Assignee: Northern Antibiotics Ltd.Inventors: Martti Sakari Vaara, Timo Ilmari Vaara
-
Publication number: 20120283175Abstract: The present invention provides a methods and pharmaceutical compositions useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, a synergistic combination of an inhibitor of LpxC and second antibacterial agent.Type: ApplicationFiled: November 4, 2011Publication date: November 8, 2012Applicant: Achaogen, Inc.Inventors: Phillip A. Patten, Eliana Saxon Armstrong
-
Publication number: 20120277145Abstract: The present invention pertains generally to certain compounds of the deoxyactagardine A and B type. Such compounds are suitable for use in the treatment of microbial infections, for example Clostridium infection, such as C. perfringens, C. difficile, C. tetani, and/or C. botulinum, in particular C. difficile, especially infection of the colon and/or lower intestines and diarrhoea associated with the microbial infection.Type: ApplicationFiled: May 21, 2012Publication date: November 1, 2012Inventor: Sjoerd Nicolaas Wadman
-
Patent number: 8257478Abstract: Compounds originally isolated from marine fungi are useful as antifouling (antibacterial and/or anti-larval settlement) agents. The compounds are 3-chloro-2,5-dihydroxy benzyl alcohol, cyclo-(Pro-Phe),3-methyl-N-(2-phenylethyl) butanamide, and succinic acid. The compounds are non-toxic or low-toxic. They can be used alone or in combination, as active ingredients for making environment-friendly antifouling formulations/coatings.Type: GrantFiled: December 16, 2005Date of Patent: September 4, 2012Assignee: The Hong Kong University of Science and TechnologyInventors: Pei-Yuan Qian, Xiancui Li, Fuk Ning Kwong, Lai Hung Yang, Sergey Vladimirovich Dobretsov
-
Patent number: 8247372Abstract: Compounds which are Spiruchostatin analogues of the general formula (I) or (I?), isosteres thereof and pharmaceutically acceptable salts thereof are found to inhibit HDAC wherein R1, R2, R3 and R4 are the same or different and represent an amino acid side chain moiety and each R6 is the same or different and represents hydrogen or C1-C4 alkyl.Type: GrantFiled: November 23, 2007Date of Patent: August 21, 2012Assignee: University of SouthamptonInventors: Graham Keith Packham, Arasu Ganesan, Alexander Richard Liam Cecil
-
Publication number: 20120207822Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with 3,3-dimethyl-1-butanol (DMB) and related compounds, and pharmaceutical formulations thereof. In other embodiments, the present invention provides methods of administering a gut flora targeting antibiotic to a subject prior to a procedure that is associated with a risk of causing thrombosis, heart-attack, and/or platelet hyper-responsiveness.Type: ApplicationFiled: February 1, 2012Publication date: August 16, 2012Inventors: Stanley Hazen, Zeneng Wang
-
Publication number: 20120202737Abstract: The invention concerns new Bacitracin compounds containing methylene-isoleucine.Type: ApplicationFiled: September 30, 2010Publication date: August 9, 2012Applicant: XELLIA PHARMACEUTICALS APSInventors: Martin Mansson, Christine Senstad
-
Publication number: 20120196791Abstract: Methods for treating a bacterial infection in a mammal in need thereof, and compositions related thereto, are disclosed, the methods comprising administering to the mammal an effective amount of an antibacterial aminoglycoside compound and a second antibacterial agent.Type: ApplicationFiled: December 15, 2011Publication date: August 2, 2012Applicant: Achaogen, Inc.Inventors: Eliana Saxon Armstrong, Jon B. Bruss
-
Publication number: 20120189711Abstract: Extracorporeal systems and methods for treating blood-borne diseases in a subject or for developing drugs to treat blood-borne diseases include various environmental and treatment modules that can be tailored to a specific disease or infection. In certain embodiments of the systems and methods, a blood sample is treated with hydrostatic pressure, a pulsed electrical field, a pharmaceutical agent, microwave, centrifugation, sonification, radiation, or a combination thereof, under environmental conditions that are effective for the treatment.Type: ApplicationFiled: January 9, 2012Publication date: July 26, 2012Applicant: Somerset Group Enterprises, Inc.Inventors: David G. Greenberg, Scott Puritz, Tatiana Koutchma, Juan N. Walterspiel
-
Publication number: 20120172289Abstract: The present invention relates to a compound of formula (I) and compositions thereof, methods of their production as well as methods for treating bacterial infection.Type: ApplicationFiled: December 28, 2011Publication date: July 5, 2012Applicant: NANYANG TECHNOLOGICAL UNIVERSITYInventors: Bengang Xing, Tingting Jiang, Roushen Liew
-
Patent number: 8211855Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.Type: GrantFiled: September 18, 2007Date of Patent: July 3, 2012Assignee: Allergan, Inc.Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone